<DOC>
	<DOCNO>NCT01021397</DOCNO>
	<brief_summary>Human parainfluenza virus ( HPIVs ) major health concern infant young child 5 year age , cause serious respiratory tract disease . The primary purpose study test safety immune response new HPIV vaccine healthy infant child .</brief_summary>
	<brief_title>Safety Immune Response Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine Healthy Infants Children</brief_title>
	<detailed_description>HPIV type 3 ( HPIV3 ) rank second respiratory syncytial virus important cause bronchiolitis pneumonia infant less 6 month age . HPIV3 cause severe disease first 2 year life responsible 11 % hospitalization respiratory diseases child . This study evaluate safety immunogenicity live recombinant attenuate intranasal HPIV3 vaccine , rHPIV3cp45 . This study last approximately 28 week . Infants child 6 month 36 month age randomly assign one two group . Group 1 participant receive 2 immunization rHPIV3cp45 . Group 2 participant receive 2 dos rHPIV3cp45 placebo . Immunizations give nose drop administer study entry approximately 22 27 week study entry . On day immunization , physical exam blood collection occur . Participants observe 15 minute immunization immediate adverse effect . Parents guardian give thermometer take instructed take child 's temperature . They give study schedule need provide contact phone number study personnel contact phone day immunization . Parents guardian contact telephone daily Day 1 Day 18 immunization . Parents guardian need record child 's temperature daily least 17 day immediately follow immunization . During 17-day period , study visit occur Days 3 , 6 , 12 dose vaccine placebo . Participants undergo nasal wash viral culture study visit . There additional follow-up visit occur sometime 49 63 day first dose 28 35 day second dose ; blood collection occur follow-up visit . Additional visit may require selected day month immunization . Infants experience illness side effect may ask return clinic examination .</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Paramyxoviridae Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Good general health HPIV3uninfected Has receive ageappropriate inactivate subunit routine immunization least 2 week prior study entry Has receive ageappropriate live routine immunization least 4 week prior study entry least 2 week rotavirus inactivate vaccine Available duration trial Parent guardian reachable telephone postimmunization contact Parent guardian willing provide inform consent Known suspect impairment immunologic function . Infants HIVinfected , bone marrow solid organ transplant recipient , receive immunosuppressive therapy , include systemic corticosteroid within 30 day prior study entry . Infants use topical steroid , topical antibiotic ointment topical antifungal agent exclude . Major congenital malformation , include congenital cleft palate , cytogenetic abnormality , serious chronic disorder Previously receive HPIV3 vaccine Previous serious vaccineassociated adverse event anaphylactic reaction Known hypersensitivity vaccine component Lung heart disease , include reactive airway disease . Infants clinically insignificant cardiac abnormality exclude . Infants child wheeze receive bronchodilator therapy first year life additional wheezing episode bronchodilator therapy least 12 month exclude . Born prematurely 37th week pregnancy participant currently less 12 month age Member household contain immunocompromised individual , pregnant caregiver , infant le 6 month age Attends day care infant less 6 month age Parent guardian unable unwilling suspend daycare 14 day follow immunization . More information criterion find protocol . Enrolled another investigational drug vaccine study 30 day prior study entry final followup blood draw</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>36 Months</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Respiratory Tract Infection</keyword>
</DOC>